Cargando…

1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach

BACKGROUND: Vancomycin (VAN) is renally eliminated and clearance (CL) correlates with glomerular filtration rate (GFR). The bedside Schwartz equation (Schwartz(bed)), currently used to estimate GFR in children, relies solely on creatinine (Cr) and is inaccurate in critical illness. We compared the S...

Descripción completa

Detalles Bibliográficos
Autores principales: Downes, Kevin, Zuppa, Athena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254693/
http://dx.doi.org/10.1093/ofid/ofy210.1233
_version_ 1783373782452273152
author Downes, Kevin
Zuppa, Athena
author_facet Downes, Kevin
Zuppa, Athena
author_sort Downes, Kevin
collection PubMed
description BACKGROUND: Vancomycin (VAN) is renally eliminated and clearance (CL) correlates with glomerular filtration rate (GFR). The bedside Schwartz equation (Schwartz(bed)), currently used to estimate GFR in children, relies solely on creatinine (Cr) and is inaccurate in critical illness. We compared the Schwartz(bed) against various GFR-estimating equations that incorporate the novel biomarker cystatin C (CysC) in a population pharmacokinetic (PK) model of VAN CL in critically ill children. METHODS: Children 2–18 years of age receiving intravenous VAN in the Children’s Hospital of Philadelphia PICU were enrolled. Three PK samples were collected during a single steady-state dosing interval in addition to VAN concentrations collected for clinical care. A sample was obtained prior to and during PK sampling for the measurement of CysC and Cr. VAN concentrations, dosing histories, and covariates (age, height, weight, sex, eGFR) were analyzed using nonlinear mixed-effects modeling with NONMEM v7.4. Model evaluation/selection was based on successful convergence, precision of the parameter estimates, the Akaike Information Criteria (AIC), and comparison of goodness-of-fit diagnostic plots of models including Schwartz(bed)and other published Cr- and CysC-based eGFR equations. RESULTS: We enrolled 20 subjects age 12.7 years (range: 3.9–18.2); six were female. Median VAN dosing at PK sampling was 57.4 mg/kg/day (range: 26.4–80.1). Median Cr was 0.35 mg/dL (IQR 0.3–0.5) and CysC was 0.5 mg/L (IQR 0.4–0.8); correlation between Cr and CysC was poor (0.24). Population PK data were described by a two-compartment model with allometric scaling for all parameters. The full age spectrum equation using both Cr and CysC [eGFR = 107.3/((Cr/Q(Cr))*0.5 + (CysC/Q(CysC))*0.5); Q(Cr) and Q(CysC) are normal values for age] as a covariate on CL had the largest reduction in AIC compared with Schwartz(bed) (ΔAIC −11.571) and provided best model fit. Typical population PK parameters (95% CI) normalized to 70 kg were 0.13 L/minute (0.11,0.14), 24.5 L (7.7,41.5), and 0.14 L/minute (0.01, 0.28) for CL, V1, and Q, respectively. CONCLUSION: Incorporation of eGFR calculated using the Cr- and CysC-based full age spectrum equation improved population PK model fit for VAN among critically ill children compared with Schwartz(bed). Clinical use of CysC may help estimate VAN CL among critically ill children compared with use of Cr alone. DISCLOSURES: K. Downes, Merck, Inc.: Investigator, Research support. Pfizer, Inc.: Investigator, Research support.
format Online
Article
Text
id pubmed-6254693
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62546932018-11-28 1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach Downes, Kevin Zuppa, Athena Open Forum Infect Dis Abstracts BACKGROUND: Vancomycin (VAN) is renally eliminated and clearance (CL) correlates with glomerular filtration rate (GFR). The bedside Schwartz equation (Schwartz(bed)), currently used to estimate GFR in children, relies solely on creatinine (Cr) and is inaccurate in critical illness. We compared the Schwartz(bed) against various GFR-estimating equations that incorporate the novel biomarker cystatin C (CysC) in a population pharmacokinetic (PK) model of VAN CL in critically ill children. METHODS: Children 2–18 years of age receiving intravenous VAN in the Children’s Hospital of Philadelphia PICU were enrolled. Three PK samples were collected during a single steady-state dosing interval in addition to VAN concentrations collected for clinical care. A sample was obtained prior to and during PK sampling for the measurement of CysC and Cr. VAN concentrations, dosing histories, and covariates (age, height, weight, sex, eGFR) were analyzed using nonlinear mixed-effects modeling with NONMEM v7.4. Model evaluation/selection was based on successful convergence, precision of the parameter estimates, the Akaike Information Criteria (AIC), and comparison of goodness-of-fit diagnostic plots of models including Schwartz(bed)and other published Cr- and CysC-based eGFR equations. RESULTS: We enrolled 20 subjects age 12.7 years (range: 3.9–18.2); six were female. Median VAN dosing at PK sampling was 57.4 mg/kg/day (range: 26.4–80.1). Median Cr was 0.35 mg/dL (IQR 0.3–0.5) and CysC was 0.5 mg/L (IQR 0.4–0.8); correlation between Cr and CysC was poor (0.24). Population PK data were described by a two-compartment model with allometric scaling for all parameters. The full age spectrum equation using both Cr and CysC [eGFR = 107.3/((Cr/Q(Cr))*0.5 + (CysC/Q(CysC))*0.5); Q(Cr) and Q(CysC) are normal values for age] as a covariate on CL had the largest reduction in AIC compared with Schwartz(bed) (ΔAIC −11.571) and provided best model fit. Typical population PK parameters (95% CI) normalized to 70 kg were 0.13 L/minute (0.11,0.14), 24.5 L (7.7,41.5), and 0.14 L/minute (0.01, 0.28) for CL, V1, and Q, respectively. CONCLUSION: Incorporation of eGFR calculated using the Cr- and CysC-based full age spectrum equation improved population PK model fit for VAN among critically ill children compared with Schwartz(bed). Clinical use of CysC may help estimate VAN CL among critically ill children compared with use of Cr alone. DISCLOSURES: K. Downes, Merck, Inc.: Investigator, Research support. Pfizer, Inc.: Investigator, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6254693/ http://dx.doi.org/10.1093/ofid/ofy210.1233 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Downes, Kevin
Zuppa, Athena
1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
title 1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
title_full 1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
title_fullStr 1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
title_full_unstemmed 1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
title_short 1402. Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach
title_sort 1402. cystatin c improves estimation of vancomycin clearance in critically ill children using a population pharmacokinetic modeling approach
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254693/
http://dx.doi.org/10.1093/ofid/ofy210.1233
work_keys_str_mv AT downeskevin 1402cystatincimprovesestimationofvancomycinclearanceincriticallyillchildrenusingapopulationpharmacokineticmodelingapproach
AT zuppaathena 1402cystatincimprovesestimationofvancomycinclearanceincriticallyillchildrenusingapopulationpharmacokineticmodelingapproach